Reported 4 days ago
Stifel has cut its price target for Maravai Lifesciences (MRVI) from $10 to $5 while maintaining a Buy rating. The firm noted that the company's Q4 revenues and EBITDA fell short of expectations, and management's guidance is below market forecasts amid uncertainties regarding post-COVID demand and operations in China. The firm views Maravai as currently underpriced but advises caution until clearer growth prospects emerge.
Source: YAHOO